Instil Bio
38 hedge funds and large institutions have $96.9M invested in Instil Bio in 2025 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 7 increasing their positions, 13 reducing their positions, and 12 closing their positions.
6% more capital invested
Capital invested by funds: $91.2M → $96.9M (+$5.68M)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
9.54% less ownership
Funds ownership: 80.44% → 70.9% (-9.5%)
12% less funds holding
Funds holding: 43 → 38 (-5)
25% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 12
46% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$2.47M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$1.8M |
| 3 |
Morgan Stanley
New York
|
+$1.61M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$1.35M |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$1.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$6.12M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
-$4.78M |
| 3 |
Millennium Management
New York
|
-$2.18M |
| 4 |
O
OrbiMed
New York
|
-$2.03M |
| 5 |
VCIM
Velan Capital Investment Management
Alpharetta,
Georgia
|
-$1.2M |
TIL Hedge Fund Activity: Q2 2025 in Review
38 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Instil Bio (TIL) for Q2 2025, worth a combined $96.9M — up 6.2% from $91.2M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of TIL and 9 opened new positions — a net loss of 3 holders — while 13 trimmed existing stakes and 7 added.
The largest buyer was BML Capital Management, adding an estimated $2.47M. The largest seller was Vivo Capital, cutting an estimated $6.12M.
- 38 institutional investors held Instil Bio (TIL) as of Q2 2025, down from 43 in Q1 2025.
- Funds reported $96.9M of Instil Bio stock for Q2 2025, up 6.2% quarter-over-quarter.
- 9 funds opened new Instil Bio positions in Q2 2025 and 12 closed out, a net change of -3 holders.
- The largest Instil Bio buyer in Q2 2025 was BML Capital Management, an estimated $2.47M added.
- The largest Instil Bio seller in Q2 2025 was Vivo Capital, an estimated $6.12M sold.
Based on aggregated 13F filings for Q2 2025.